Irritable bowel syndrome (Blautix)

We are currently conducting a phase II study of Blautix in IBS-Constipation predominant and IBS-Diarrhoea predominant type patients in Europe and the USA.

Details of the study can be found here.

In 2016 we completed a Phase Ib study of Blautix, our live biotherapeutic candidate for irritable bowel syndrome (IBS).

The study met its primary objective of demonstrating that Blautix was safe and well tolerated. Encouragingly, we saw a greater proportion of Blautix-treated patients showing improvements in their IBS symptoms compared with patients receiving placebo. We also noted a greater proportion of the Blautix treatment group exhibiting a reduction in hydrogen breath levels – a biomarker of the drug’s activity. Analysis of patient samples using our proprietary microbiome profiling platform, MicroDx, showed that the administration of Blautix resulted in an increase in microbiome diversity.

Oncology (MRx0518)

4D’s MRx0518 is a live biotherapeutic candidate for cancer. We are investigating the effects of this candidate in a wide range of solid tumour types.

Phase I/II combination study

In collaboration with Merck & Co., known as MSD outside the United States and Canada, we are conducting a Phase I/II investigation of the combination of MRx0518 and Keytruda (pembrolizumab) in patients who with advanced and/or metastatic non-small cell lung cancer, kidney cancer, bladder cancer or melanoma who have failed prior anti-PD-1 therapy. This study is taking place in the United States.

Details of the study can be found here.

Phase Ib monotherapy study

A Phase Ib study for patients with solid tumours that have received no prior treatment and are due to undergo surgical removal of the tumour is enrolling. This study is being conducted in London, UK.

Details of the study can be found here.

If you are interested in participating in these studies, please e-mail